stage 3 squamous lung cancer with low pd-l1 - case based panel discussion
Published 2 years ago • 250 plays • Length 6:30Download video MP4
Download video MP3
Similar videos
-
9:21
case based panel discussions - metastatic squamous nsclc low tumor pd-l1 frail patient - treatment?
-
12:59
case based panel discussion - adv non squamous nsclc, low pd-l1 no mutation - best systemic therapy?
-
10:08
case based panel discussion stage 3 nsclc - does timing of treatment make a difference in response.
-
5:17
immunotherapy in stage iii nsclc - case based panel discussion
-
6:17
case based panel discussion - stage 3 nsclc - patients with pdl1 - 0, is immunotherapy beneficial?
-
3:48
treating stage iii nsclc - case based panel discussion
-
8:16
case based panel discussion - stage 3 nsclc best schedule - durvalumab/imfinzi in varying patients
-
11:27
case based panel discussion - stage 3 nsclc, frail patient competing risks, best treatment approach?
-
8:17
case based panel discussion - rapid progression adenocarcinoma high pd-l1 - how do you treat?
-
4:34
case based panel discussion - stage 3 nsclc treatment standard and the risk of potential pneumonitis
-
13:00
stage 3a node-positive lung adenocarcinoma with alk rearrangement - case based panel discussions
-
5:06
case based panel discussion - egfr mutation and high pdl1 - what is the role of immunotherapy in tre
-
11:25
case based panel discussion - stage3 nsclc should we do molecular tests? effect treatment decision?
-
2:02
progression on pembrolizumab: patient without actionable mutations & low pd-l1 - lung cancer onctalk
-
7:44
treatment for kras g12c mutated nsclc with high tumor mutational burden -case-based panel discussion
-
6:29
case based panel discussion nsclc – does a positive her2 mutation effect treatment decisions?
-
7:12
egfr mutated adenocarcinoma - case based panel discussions